{"id":41109,"date":"2026-03-23T08:22:48","date_gmt":"2026-03-23T12:22:48","guid":{"rendered":"https:\/\/tvdelmarva.com\/wp\/french-pharma-giant-partners-with-kali-therapeutics-for-autoimmune-drug-development\/"},"modified":"2026-03-23T08:22:48","modified_gmt":"2026-03-23T12:22:48","slug":"french-pharma-giant-partners-with-kali-therapeutics-for-autoimmune-drug-development","status":"publish","type":"post","link":"https:\/\/tvdelmarva.com\/wp\/french-pharma-giant-partners-with-kali-therapeutics-for-autoimmune-drug-development\/","title":{"rendered":"French Pharma Giant Partners with Kali Therapeutics for Autoimmune Drug Development"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n

A biotechnology company specializing in next-generation treatments has struck a significant partnership deal with one of the world’s largest pharmaceutical manufacturers to advance a promising autoimmune therapy.<\/p>

Kali Therapeutics announced Monday that it has formed a licensing partnership with Sanofi, the French pharmaceutical giant, to further develop the company’s experimental autoimmune disease treatment called KT501.<\/p>

The financial terms of the agreement are substantial. Kali Therapeutics will collect $180 million in immediate and short-term payments, with the potential to earn an additional $1.05 billion through various development and sales milestones. Should the treatment receive regulatory approval, the company will earn royalty payments ranging from high single-digit to double-digit percentages on product sales.<\/p>

Through this partnership, Sanofi gains worldwide rights to KT501, which represents a tri-specific antibody created using Kali Therapeutics’ proprietary research platform. The experimental drug is currently undergoing early-phase clinical testing in rheumatoid arthritis patients to evaluate safety and patient tolerance levels.<\/p>

According to Kali Therapeutics, the treatment is engineered to target and regulate immune cells responsible for triggering autoimmune conditions, including diseases like lupus and rheumatoid arthritis. Laboratory studies conducted on non-human primates demonstrated that KT501 significantly decreased B cell populations\u2014a type of white blood cell\u2014while minimizing the dangerous immune responses sometimes associated with comparable therapies.<\/p>

Sanofi brings existing expertise in autoimmune treatments to the partnership, currently selling Kevzara, an approved rheumatoid arthritis medication developed in collaboration with Regeneron Pharmaceuticals. The company is simultaneously working on additional anti-inflammatory drug candidates in its pipeline.<\/p>","protected":false},"excerpt":{"rendered":"

Kali Therapeutics announced a major licensing partnership with French pharmaceutical company Sanofi to advance development of an experimental autoimmune disease treatment. The deal includes $180 million in initial payments and potential milestone payments reaching $1.05 billion.<\/p>\n","protected":false},"author":4,"featured_media":41108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[834],"tags":[],"class_list":["post-41109","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774268567857.jpg?fit=450%2C307&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/pbtNqq-aH3","jetpack-related-posts":[{"id":61128,"url":"https:\/\/tvdelmarva.com\/wp\/belgium-drug-company-acquires-california-biotech-firm-for-2-2-billion\/","url_meta":{"origin":41109,"position":0},"title":"Belgium Drug Company Acquires California Biotech Firm for $2.2 Billion","author":"Admin","date":"May 3, 2026","format":false,"excerpt":"Belgian pharmaceutical company UCB announced Sunday it will acquire California-based Candid Therapeutics in a deal valued at up to $2.2 billion. The acquisition targets Candid's autoimmune disease treatment development programs.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777832547142.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777832547142.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777832547142.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777832547142.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777832547142.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":31385,"url":"https:\/\/tvdelmarva.com\/wp\/chinese-biotech-company-strikes-major-deal-with-belgian-pharmaceutical-giant\/","url_meta":{"origin":41109,"position":1},"title":"Chinese Biotech Company Strikes Major Deal with Belgian Pharmaceutical Giant","author":"Admin","date":"March 4, 2026","format":false,"excerpt":"A Chinese biotechnology firm has secured a significant licensing agreement worth potentially over $1 billion for an experimental autoimmune disease treatment. The partnership with Belgium-based UCB includes $60 million upfront with additional milestone payments.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772601594607.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772601594607.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772601594607.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772601594607.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772601594607.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":62482,"url":"https:\/\/tvdelmarva.com\/wp\/german-pharma-giant-bayer-acquires-biotech-firm-for-2-45-billion\/","url_meta":{"origin":41109,"position":2},"title":"German Pharma Giant Bayer Acquires Biotech Firm for $2.45 Billion","author":"Admin","date":"May 6, 2026","format":false,"excerpt":"Pharmaceutical company Bayer announced Wednesday it will acquire biopharmaceutical firm Perfuse Therapeutics in a deal worth up to $2.45 billion. The acquisition is designed to strengthen Bayer's eye care treatment development portfolio.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778052230771.jpg?fit=450%2C313&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":51565,"url":"https:\/\/tvdelmarva.com\/wp\/fda-approves-first-treatment-for-rare-kidney-disease-affecting-40000-americans\/","url_meta":{"origin":41109,"position":3},"title":"FDA Approves First Treatment for Rare Kidney Disease Affecting 40,000 Americans","author":"Admin","date":"April 13, 2026","format":false,"excerpt":"Federal health regulators have given the green light for expanded use of Travere Therapeutics' medication to treat a rare kidney condition. The drug, Sparsentan, becomes the first FDA-approved treatment for focal segmental glomerulosclerosis, which can cause kidney failure.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1776122533317.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":54562,"url":"https:\/\/tvdelmarva.com\/wp\/pharmaceutical-giant-eli-lilly-eyes-2b-deal-for-kelonia-therapeutics\/","url_meta":{"origin":41109,"position":4},"title":"Pharmaceutical Giant Eli Lilly Eyes $2B+ Deal for Kelonia Therapeutics","author":"Admin","date":"April 19, 2026","format":false,"excerpt":"Major drug manufacturer Eli Lilly is reportedly close to finalizing a purchase of Kelonia Therapeutics worth more than $2 billion. The Wall Street Journal broke the story on Sunday, though the details have not been independently confirmed.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1776637345643.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":43193,"url":"https:\/\/tvdelmarva.com\/wp\/swiss-drug-giant-novartis-strikes-2b-deal-for-california-biotech-company\/","url_meta":{"origin":41109,"position":5},"title":"Swiss Drug Giant Novartis Strikes $2B Deal for California Biotech Company","author":"Admin","date":"March 27, 2026","format":false,"excerpt":"Pharmaceutical giant Novartis announced Friday it will purchase California-based Excellergy for up to $2 billion. The acquisition aims to boost Novartis' position in food allergy treatments and follows another major biotech purchase last week.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774596216914.jpg?fit=450%2C321&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/41109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/comments?post=41109"}],"version-history":[{"count":0,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/41109\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media\/41108"}],"wp:attachment":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media?parent=41109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/categories?post=41109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/tags?post=41109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}